Comparison of the Effectiveness of Bosentan and Sildenafil in the Management of Persistent Pulmonary Arterial Hypertension in Neonates [PDF]
, 2022 Hanan Elsayed Kamel Bakry
openalex +1 more source
Principles of pharmacological correction of pulmonary arterial hypertension [PDF]
, 2018 Prostanoids are a promising group of drugs for the treatment of pulmonary arterial hypertension (PAH), since they possess not only vasodilating, but also antiplatelet and antiproliferative actions.
Korokin, M. V. +3 more
core +2 more sources
Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. [PDF]
, 2014 This is the final version of the article. It first appeared from Wiley via http://dx.doi.org/10.1111/bph.12874Since the discovery of endothelin (ET)-1 in 1988, the main components of the signalling pathway have become established, comprising three ...
Davenport, AP, Maguire, JJ
core +4 more sources
Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. [PDF]
, 2017 Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial pneumonia of unknown etiology, primarily affects older adults and leads to a progressive decline in lung function and quality of life.
Collard, Harold R, Oldham, Justin M
core +2 more sources
Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: A case report [PDF]
, 2008 Konrad Höetzenecker +6 more
openalex +1 more source
Left main bronchus compression due to main pulmonary artery dilatation in pulmonary hypertension: two case reports [PDF]
, 2015 . Pulmonary arterial dilatation associated with pulmonary hypertension may result in significant compression of local structures. Left main coronary artery and left recurrent laryngeal nerve compression have been described.
Ariff, B +6 more
core +1 more source
Effects of the non‐peptide, non‐selective endothelin antagonist, bosentan, on regional haemodynamic responses to NG‐monomethyl‐L‐arginine in conscious rats [PDF]
, 1996 Sheila M. Gardiner +3 more
openalex +1 more source
Canadian Respiratory Journal, 2006 BACKGROUND: Bosentan has been shown to be a safe and efficacious treatment for idiopathic pulmonary arterial hypertension (PAH) and PAH associated with connective tissue disease.
Reda Ibrahim +2 more
doaj +1 more source
Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan
BMC Cardiovascular Disorders, 2012 Background This study assessed the effectiveness and safety of bosentan when administered to thromboangiitis obliterans (Buerger's disease) patients.
De Haro Joaquin +4 more
doaj +1 more source
An Atypical Presentation of Liver Enzyme Elevation Resulting from Bosentan Use
Canadian Respiratory Journal, 2009 Hepatocellular enzyme elevation is a known side effect of both bosentan and atorvastatin. However, a rise in liver enzyme level not characteristic of either agent individually may represent a reaction to their combination or an atypical reaction to ...
Kimberley Mulchey, Zoheir Bshouty
doaj +1 more source